KUCOIN
21.11.2023 11:01:29 CET | Business Wire | Press release
KuCoin, a top 5 cryptocurrency exchange platform, is empowering the future of payment with the launch of KuCard. This groundbreaking cryptocurrency debit card seamlessly merges digital assets with traditional banking, giving users the freedom to spend their cryptocurrency anywhere that accepts regular debit cards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231121892685/en/
KuCoin, a top 5 cryptocurrency exchange platform, is empowering the future of payment with the launch of KuCard. This groundbreaking cryptocurrency debit card seamlessly merges digital assets with traditional banking, giving users the freedom to spend their cryptocurrency anywhere that accepts regular debit cards. (Photo: Business Wire)
Accepted at millions of locations, KuCard empowers users to utilize their cryptocurrency for everyday purchases, online shopping, or even withdraw cash at ATMs. KuCard simplifies the process of converting and spending cryptocurrency, eliminating the complexities of transactions or conversions typically associated with digital assets. It automatically converts cryptocurrency into local currency at the point of sale, ensuring users always get the best possible exchange rate.
KuCard prioritizes the safety of digital assets with advanced security features. Real-time notifications and detailed transaction records help users easily track and manage spending, providing peace of mind that their digital assets are safe and secure. Additionally, KuCard seamlessly integrates with Apple Pay and Google Pay, enabling contactless payments using a smartphone. This integration not only provides an additional layer of convenience but also enhances the security of transactions.
In this first phase of the launch, KuCard will be exclusively available to residents of the European Economic Area (EEA), while a global launch is on the roadmap. To be eligible, users need to pass identity verification using a supported EEA-issued ID card. Users can immediately start using virtual KuCard for purchases after their applications are approved, and physical KuCard is available upon ordering. KuCard currently supports USDT and EUR. In the future, it will support a wide range of cryptocurrencies, giving users the freedom to use the cryptocurrency of their choice.
KuCard will offer a range of innovative features and rewards, including a cashback program allowing users to earn cryptocurrency with every purchase made using the card. To celebrate the first phase of launch, KuCoin is offering a special Black Friday promotion including unlimited cashback and a $2250 bonus.
"The launch of KuCard represents a significant milestone for both KuCoin and the cryptocurrency industry as a whole, as the daily payment method, the crypto debit card plays a crucial role in accelerating the crypto mass adoption" said Johnny Lyu, CEO at KuCoin. "We are excited to offer users a seamless bridge between digital assets and traditional banking, empowering them to spend their cryptocurrency with ease while enjoying the benefits of a traditional debit card."
Experience the convenience of a traditional debit card with the flexibility and potential of cryptocurrency. Embrace the future of payment with KuCard. For more information about KuCard and its features, please visit https://www.kucoin.com/kucard.
About KuCoin
Launched in September 2017, KuCoin is a global cryptocurrency exchange with its operational headquarters in Seychelles. As a user-oriented platform with a focus on inclusiveness and community action reach, it offers over 700 digital assets and currently provides spot trading, margin trading, P2P fiat trading, futures trading, staking, and lending to its 30 million users in more than 200 countries and regions. KuCoin is currently one of the top 5 crypto exchanges according to CoinMarketCap. In 2023, KuCoin was named one of the Best Crypto Exchanges by Forbes and recognized as a highly commended global exchange in Finder's 2023 Global Cryptocurrency Trading Platform Awards.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231121892685/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom